Scientists reprogram Patients' own cells to hunt down cancer
NCT ID NCT03434769
Summary
This early-phase study is testing a new personalized treatment called CAR T-cell therapy for non-Hodgkin lymphoma that has returned or hasn't responded to standard treatments. Doctors collect a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells, then infuse them back into the patient. The main goals are to check if this approach is safe, determine the best dose, and see what side effects occur while also measuring how well the cancer responds.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.